Key statistics
On Monday, ALK-Abello A/S (0OIR:LSE) closed at 149.45, 13.82% above the 52 week low of 131.30 set on Apr 07, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | -- |
|---|---|
| High | 149.45 |
| Low | 149.45 |
| Bid | -- |
| Offer | -- |
| Previous close | 149.45 |
| Average volume | 13.24k |
|---|---|
| Shares outstanding | 202.57m |
| Free float | 112.81m |
| P/E (TTM) | 40.84 |
| Market cap | 44.65bn DKK |
| EPS (TTM) | 5.40 DKK |
| Annual div (ADY) | -- |
|---|---|
| Annual div yield (ADY) | 1.07% |
| Div ex-date | Mar 16 2017 |
| Div pay-date | Mar 20 2017 |
| Next div ex-date | Mar 17 2026 |
| Next div pay-date | Mar 19 2026 |
Data delayed at least 20 minutes, as of Mar 02 2026 17:33 GMT.
More ▼
Announcements
- Annual General Meeting in ALK-Abelló A/S on 16 March 2026
- Ordinær generalforsamling i ALK-Abelló A/S den 16. marts 2026
- Henriette Mersebach fratræder som forskningsdirektør i ALK
- Henriette Mersebach to step down as ALK’s head of R&D
- Annual report 2025: ALK delivers 15% revenue growth and 26% EBIT margin
- Invitation to the presentation of ALK’s annual report 2025 on Friday, 20 February 2026
- Invitation til præsentation af ALK’s årsrapport for 2025 fredag den 20. februar 2026
- ALK modtager anbefaling om godkendelse af EURneffy® 1 mg: En nålefri anafylaksibehandling til børn
- ALK receives positive recommendation for EURneffy® 1 mg: A needle-free anaphylaxis treatment for children
- ALK to present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco
More ▼
